Rhythm Pharmaceuticals Inc (RYTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has a cash flow conversion efficiency ratio of -0.183x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.39 Million) by net assets ($139.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Rhythm Pharmaceuticals Inc net asset quality index to measure how much of total assets are equity-financed.
Rhythm Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Rhythm Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
Rhythm Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marfrig Global Foods S.A.
SA:MRFG3
|
0.234x |
|
BILIBILI INC. DL -0001
F:71BB
|
0.128x |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
|
Ameris Bancorp
NYSE:ABCB
|
0.063x |
|
Amdocs Limited
F:AOS
|
0.064x |
|
Venture Global, Inc.
NYSE:VG
|
0.174x |
|
Red Avenue New Materials Group Co Ltd
SHG:603650
|
0.048x |
|
Fujian Wanchen Biotechnology Co. Ltd
SHE:300972
|
N/A |
Annual Cash Flow Conversion Efficiency for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rhythm Pharmaceuticals Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Rhythm Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $139.07 Million | $-115.67 Million | -0.832x | -20.19% |
| 2024-12-31 | $164.55 Million | $-113.88 Million | -0.692x | +13.71% |
| 2023-12-31 | $169.76 Million | $-136.16 Million | -0.802x | -22.21% |
| 2022-12-31 | $264.26 Million | $-173.43 Million | -0.656x | -27.72% |
| 2021-12-31 | $284.15 Million | $-146.00 Million | -0.514x | +29.85% |
| 2020-12-31 | $166.53 Million | $-121.98 Million | -0.732x | -67.69% |
| 2019-12-31 | $281.02 Million | $-122.75 Million | -0.437x | -73.34% |
| 2018-12-31 | $246.26 Million | $-62.06 Million | -0.252x | -23.85% |
| 2017-12-31 | $144.79 Million | $-29.46 Million | -0.203x | +93.61% |
| 2016-12-31 | $7.30 Million | $-23.22 Million | -3.182x | -1359.47% |
| 2015-12-31 | $32.00 Million | $-6.98 Million | -0.218x | -101.04% |
| 2014-12-31 | $-358.00K | $-7.51 Million | 20.972x | +6190.74% |
| 2013-12-31 | $-57.46 Million | $-19.16 Million | 0.333x | -32.16% |
| 2012-12-31 | $-36.28 Million | $-17.83 Million | 0.491x | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more